Search

Your search keyword '"Kim, Tae Won"' showing total 2,903 results
Start Over Author "Kim, Tae Won"
2,903 results on '"Kim, Tae Won"'

1. Dequantizability from inputs

Author

Kim, Tae-Won and Choi, Byung-Soo

Subjects
Quantum Physics, Computer Science - Computational Complexity, Computer Science - Data Structures and Algorithms
Abstract

By comparing constructions of block encoding given by [1-4], we propose a way to extract dequantizability from advancements in dequantization techniques that have been led by Tang, as in [5]. Then we apply this notion to the sparse-access input model that is known to be BQP-complete in general, thereby conceived to be un-dequantizable. Our goal is to break down this belief by examining the sparse-access input model's instances, particularly their input matrices. In conclusion, this paper forms a dequantizability-verifying scheme that can be applied whenever an input is given.

Published
2024

6. Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial

Author

Desai, Jayesh, Alonso, Guzman, Kim, Se Hyun, Cervantes, Andres, Karasic, Thomas, Medina, Laura, Shacham-Shmueli, Einat, Cosman, Rasha, Falcon, Alejandro, Gort, Eelke, Guren, Tormod, Massarelli, Erminia, Miller, Jr., Wilson H., Paz-Ares, Luis, Prenen, Hans, Amatu, Alessio, Cremolini, Chiara, Kim, Tae Won, Moreno, Victor, Ou, Sai-Hong I., Passardi, Alessandro, Sacher, Adrian, Santoro, Armando, Stec, Rafal, Ulahannan, Susanna, Arbour, Kathryn, Lorusso, Patricia, Luo, Jia, Patel, Manish R., Choi, Yoonha, Shi, Zhen, Mandlekar, Sandhya, Lin, Mark T., Royer-Joo, Stephanie, Chang, Julie, Jun, Tomi, Dharia, Neekesh V., Schutzman, Jennifer L., and Han, Sae-Won

Published
2024
Full Text
View/download PDF

8. Narcolepsy risk loci outline role of T cell autoimmunity and infectious triggers in narcolepsy

Author

Ollila, Hanna M, Sharon, Eilon, Lin, Ling, Sinnott-Armstrong, Nasa, Ambati, Aditya, Yogeshwar, Selina M, Hillary, Ryan P, Jolanki, Otto, Faraco, Juliette, Einen, Mali, Luo, Guo, Zhang, Jing, Han, Fang, Yan, Han, Dong, Xiao Song, Li, Jing, Zhang, Jun, Hong, Seung-Chul, Kim, Tae Won, Dauvilliers, Yves, Barateau, Lucie, Lammers, Gert Jan, Fronczek, Rolf, Mayer, Geert, Santamaria, Joan, Arnulf, Isabelle, Knudsen-Heier, Stine, Bredahl, May Kristin Lyamouri, Thorsby, Per Medbøe, Plazzi, Giuseppe, Pizza, Fabio, Moresco, Monica, Crowe, Catherine, Van den Eeden, Stephen K, Lecendreux, Michel, Bourgin, Patrice, Kanbayashi, Takashi, Martínez-Orozco, Francisco J, Peraita-Adrados, Rosa, Benetó, Antonio, Montplaisir, Jacques, Desautels, Alex, Huang, Yu-Shu, Jennum, Poul, Nevsimalova, Sona, Kemlink, David, Iranzo, Alex, Overeem, Sebastiaan, Wierzbicka, Aleksandra, Geisler, Peter, Sonka, Karel, Honda, Makoto, Högl, Birgit, Stefani, Ambra, Coelho, Fernando Morgadinho, Mantovani, Vilma, Feketeova, Eva, Wadelius, Mia, Eriksson, Niclas, Smedje, Hans, Hallberg, Pär, Hesla, Per Egil, Rye, David, Pelin, Zerrin, Ferini-Strambi, Luigi, Bassetti, Claudio L, Mathis, Johannes, Khatami, Ramin, Aran, Adi, Nampoothiri, Sheela, Olsson, Tomas, Kockum, Ingrid, Partinen, Markku, Perola, Markus, Kornum, Birgitte R, Rueger, Sina, Winkelmann, Juliane, Miyagawa, Taku, Toyoda, Hiromi, Khor, Seik-Soon, Shimada, Mihoko, Tokunaga, Katsushi, Rivas, Manuel, Pritchard, Jonathan K, Risch, Neil, Kutalik, Zoltan, O’Hara, Ruth, Hallmayer, Joachim, Ye, Chun Jimmie, and Mignot, Emmanuel J

Subjects
Medical Microbiology, Biomedical and Clinical Sciences, Clinical Sciences, Biological Sciences, Prevention, Vaccine Related, Influenza, Autoimmune Disease, Immunization, Pneumonia & Influenza, Emerging Infectious Diseases, Infectious Diseases, 2.1 Biological and endogenous factors, Aetiology, Infection, Inflammatory and immune system, Good Health and Well Being, Humans, Autoimmunity, Influenza, Human, Influenza A Virus, H1N1 Subtype, Autoimmune Diseases, Influenza Vaccines, Narcolepsy, FinnGen
Abstract

Narcolepsy type 1 (NT1) is caused by a loss of hypocretin/orexin transmission. Risk factors include pandemic 2009 H1N1 influenza A infection and immunization with Pandemrix®. Here, we dissect disease mechanisms and interactions with environmental triggers in a multi-ethnic sample of 6,073 cases and 84,856 controls. We fine-mapped GWAS signals within HLA (DQ0602, DQB1*03:01 and DPB1*04:02) and discovered seven novel associations (CD207, NAB1, IKZF4-ERBB3, CTSC, DENND1B, SIRPG, PRF1). Significant signals at TRA and DQB1*06:02 loci were found in 245 vaccination-related cases, who also shared polygenic risk. T cell receptor associations in NT1 modulated TRAJ*24, TRAJ*28 and TRBV*4-2 chain-usage. Partitioned heritability and immune cell enrichment analyses found genetic signals to be driven by dendritic and helper T cells. Lastly comorbidity analysis using data from FinnGen, suggests shared effects between NT1 and other autoimmune diseases. NT1 genetic variants shape autoimmunity and response to environmental triggers, including influenza A infection and immunization with Pandemrix®.

Published
2023

9. Contributors

Author

Ajithdoss, D.K., primary, Al-Humadi, Nabil, additional, Amuzie, C.J., additional, Attar, Mayssa, additional, Aulbach, Adam D., additional, Boersen, Nathan, additional, Bolger, Gordon, additional, Brown, Jennifer G., additional, Chang, T.T.A., additional, Chanut, Franck Jacques-Antoine, additional, Cheng, Z., additional, Colagiovanni, Dorothy B., additional, Colerangle, John B., additional, Collins, Roger, additional, Cristofori, Patrizia, additional, Denny, Kevin H., additional, Dill-Okubo, J., additional, Ennulat, Daniela, additional, Faqi, Ali S., additional, Farmer, John T., additional, Frantz, Stephen, additional, Freshwater, Les, additional, Gauvin, David V., additional, Goud, N.S., additional, Green, M.D., additional, Henry, Scott P., additional, Hoberman, Alan, additional, Hui, Ho-Wah, additional, Hui, Julia Y., additional, Ji, A.Y., additional, Johnson, Colleen, additional, Kile, J.W., additional, Kim, Tae-Won, additional, Koch, Elisabeth, additional, Kornbrust, Douglas, additional, Kulshreshtha, V., additional, Learn, D.B., additional, LeBaron, Mathew J., additional, Levin, Arthur A., additional, Lewis, Elise, additional, Licollari, Albert, additional, Li, X.P., additional, Loo, Deryk, additional, Luhrs, Keith A., additional, Martini, Austin, additional, McCormick, D.L., additional, Meyer-Tamaki, K.B., additional, Nicolette, John, additional, O'Carroll, Andrew, additional, Oh, Hyesun Helena, additional, Oyejide, L., additional, Peraza, Marjorie A., additional, Plassmann, Stephanie, additional, Qiao, H.W., additional, Ramos, Meg Ferrell, additional, Rehagen, D., additional, Resendez, J.C., additional, Schultze, A. Eric, additional, Seals, Jennifer R., additional, Settivari, Raja S., additional, Slauter, Ric, additional, Stahl, Kurt, additional, Stump, Donald, additional, Surapaneni, Sekhar, additional, Templin, Michael, additional, Toltin, Abigail, additional, Vidmar, Tom, additional, Vrbanac, Jim, additional, Wang, Z.J., additional, Whiteley, Laurence O., additional, Wijeyesakere, Sanjeeva, additional, Wrzesinski, Claudia, additional, Xu, Jie, additional, Yang, Ping, additional, Yoder, Lisa, additional, Younis, Husam S., additional, Zhang, Y.M., additional, and Zimmermann, Zachary J., additional

Published
2024
Full Text
View/download PDF

21. Tumor-intrinsic expression of the autophagy gene Atg16l1 suppresses anti-tumor immunity in colorectal cancer

Author

Taraborrelli, Lucia, Şenbabaoğlu, Yasin, Wang, Lifen, Lim, Junghyun, Blake, Kerrigan, Kljavin, Noelyn, Gierke, Sarah, Scherl, Alexis, Ziai, James, McNamara, Erin, Owyong, Mark, Rao, Shilpa, Calviello, Aslihan Karabacak, Oreper, Daniel, Jhunjhunwala, Suchit, Argiles, Guillem, Bendell, Johanna, Kim, Tae Won, Ciardiello, Fortunato, Wongchenko, Matthew J., de Sauvage, Frederic J., de Sousa e Melo, Felipe, Yan, Yibing, West, Nathaniel R., and Murthy, Aditya

Published
2023
Full Text
View/download PDF

36. Pembrolizumab for previously treated, microsatellite instability–high/mismatch repair–deficient advanced colorectal cancer: final analysis of KEYNOTE-164

Author

Le, Dung T., Diaz, Luis A., Jr., Kim, Tae Won, Van Cutsem, Eric, Geva, Ravit, Jäger, Dirk, Hara, Hiroki, Burge, Matthew, O’Neil, Bert H., Kavan, Petr, Yoshino, Takayuki, Guimbaud, Rosine, Taniguchi, Hiroya, Élez, Elena, Al-Batran, Salah-Eddin, Boland, Patrick M., Cui, Yi, Leconte, Pierre, Marinello, Patricia, and André, Thierry

Published
2023
Full Text
View/download PDF

37. KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors

Author

Hong, David S, Fakih, Marwan G, Strickler, John H, Desai, Jayesh, Durm, Gregory A, Shapiro, Geoffrey I, Falchook, Gerald S, Price, Timothy J, Sacher, Adrian, Denlinger, Crystal S, Bang, Yung-Jue, Dy, Grace K, Krauss, John C, Kuboki, Yasutoshi, Kuo, James C, Coveler, Andrew L, Park, Keunchil, Kim, Tae Won, Barlesi, Fabrice, Munster, Pamela N, Ramalingam, Suresh S, Burns, Timothy F, Meric-Bernstam, Funda, Henary, Haby, Ngang, Jude, Ngarmchamnanrith, Gataree, Kim, June, Houk, Brett E, Canon, Jude, Lipford, J Russell, Friberg, Gregory, Lito, Piro, Govindan, Ramaswamy, and Li, Bob T

Subjects
Clinical Research, Lung, Colo-Rectal Cancer, Lung Cancer, Cancer, Digestive Diseases, 5.1 Pharmaceuticals, 6.1 Pharmaceuticals, Development of treatments and therapeutic interventions, Evaluation of treatments and therapeutic interventions, Aged, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Dose-Response Relationship, Drug, Female, Humans, Lung Neoplasms, Male, Middle Aged, Mutation, Neoplasms, Piperazines, Proto-Oncogene Proteins p21(ras), Pyridines, Pyrimidines, Medical and Health Sciences, General & Internal Medicine
Abstract

BackgroundNo therapies for targeting KRAS mutations in cancer have been approved. The KRAS p.G12C mutation occurs in 13% of non-small-cell lung cancers (NSCLCs) and in 1 to 3% of colorectal cancers and other cancers. Sotorasib is a small molecule that selectively and irreversibly targets KRASG12C.MethodsWe conducted a phase 1 trial of sotorasib in patients with advanced solid tumors harboring the KRAS p.G12C mutation. Patients received sotorasib orally once daily. The primary end point was safety. Key secondary end points were pharmacokinetics and objective response, as assessed according to Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1.ResultsA total of 129 patients (59 with NSCLC, 42 with colorectal cancer, and 28 with other tumors) were included in dose escalation and expansion cohorts. Patients had received a median of 3 (range, 0 to 11) previous lines of anticancer therapies for metastatic disease. No dose-limiting toxic effects or treatment-related deaths were observed. A total of 73 patients (56.6%) had treatment-related adverse events; 15 patients (11.6%) had grade 3 or 4 events. In the subgroup with NSCLC, 32.2% (19 patients) had a confirmed objective response (complete or partial response) and 88.1% (52 patients) had disease control (objective response or stable disease); the median progression-free survival was 6.3 months (range, 0.0+ to 14.9 [with + indicating that the value includes patient data that were censored at data cutoff]). In the subgroup with colorectal cancer, 7.1% (3 patients) had a confirmed response, and 73.8% (31 patients) had disease control; the median progression-free survival was 4.0 months (range, 0.0+ to 11.1+). Responses were also observed in patients with pancreatic, endometrial, and appendiceal cancers and melanoma.ConclusionsSotorasib showed encouraging anticancer activity in patients with heavily pretreated advanced solid tumors harboring the KRAS p.G12C mutation. Grade 3 or 4 treatment-related toxic effects occurred in 11.6% of the patients. (Funded by Amgen and others; CodeBreaK100 ClinicalTrials.gov number, NCT03600883.).

Published
2020

38. Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability–High/Mismatch Repair–Deficient Metastatic Colorectal Cancer: KEYNOTE-164

Author

Le, Dung T, Kim, Tae Won, Van Cutsem, Eric, Geva, Ravit, Jäger, Dirk, Hara, Hiroki, Burge, Matthew, O’Neil, Bert, Kavan, Petr, Yoshino, Takayuki, Guimbaud, Rosine, Taniguchi, Hiroya, Elez, Elena, Al-Batran, Salah-Eddin, Boland, Patrick M, Crocenzi, Todd, Atreya, Chloe E, Cui, Yi, Dai, Tong, Marinello, Patricia, Diaz, Luis A, and André, Thierry

Subjects
Digestive Diseases, Colo-Rectal Cancer, Cancer, Clinical Research, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Immunological, Cohort Studies, Colorectal Neoplasms, DNA Mismatch Repair, Drug Administration Schedule, Female, Humans, Infusions, Intravenous, Male, Microsatellite Instability, Middle Aged, Treatment Outcome, Young Adult, Clinical Sciences, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PurposeKEYNOTE-164 (NCT02460198) evaluated the antitumor activity of pembrolizumab in previously treated, metastatic, microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) colorectal cancer (CRC).MethodsThis phase II open-label study involved 128 centers worldwide. Eligible patients were age ≥ 18 years and had metastatic MSI-H/dMMR CRC treated with ≥ 2 prior lines of standard therapy, including fluoropyrimidine, oxaliplatin, and irinotecan with or without anti-vascular endothelial growth factor/epidermal growth factor receptor monoclonal antibody (cohort A) or ≥ 1 prior line of therapy (cohort B). MSI-H/dMMR status was assessed locally. Patients received pembrolizumab 200 mg every 3 weeks for up to 2 years until progression, unacceptable toxicity, or withdrawal. The primary end point was objective response rate by RECIST version 1.1 by independent central review. Secondary end points were duration of response, progression-free survival (PFS), overall survival, safety, and tolerability.ResultsA total of 124 patients with MSI-H/dMMR CRC (61 in cohort A, 63 in cohort B) enrolled. At data cutoff, median follow-up was 31.3 months (range, 0.2-35.6 months) for cohort A and 24.2 months (range, 0.1-27.1 months) for cohort B. Objective response rate was 33% (95% CI, 21% to 46%) and 33% (95% CI, 22% to 46%), respectively, with median duration of response not reached in either cohort. Median PFS was 2.3 months (95% CI, 2.1 to 8.1 months) and 4.1 months (95% CI, 2.1 to 18.9 months). Median overall survival was 31.4 months (95% CI, 21.4 months to not reached) and not reached (95% CI, 19.2 months to not reached). Treatment-related grade 3-4 adverse events occurred in 10 patients (16%) in cohort A and 8 (13%) in cohort B, with the most common occurring in ≥ 2 patients being pancreatitis, fatigue, increased alanine aminotransferase, and increased lipase (2 patients each; 3%) in cohort A.ConclusionPembrolizumab is effective with a manageable safety profile in patients with MSI-H/dMMR CRC.

Published
2020

45. Overall survival (OS) of phase 3 CodeBreaK 300 study of sotorasib plus panitumumab (soto+pani) versus investigator’s choice of therapy for KRAS G12C-mutated metastatic colorectal cancer (mCRC).

Author

Fakih, Marwan, primary, Salvatore, Lisa, additional, Esaki, Taito, additional, Modest, Dominik Paul, additional, Páez Lopez-Bravo, David, additional, Taieb, Julien, additional, Karamouzis, Michalis, additional, Ruiz-Garcia, Erika, additional, Kim, Tae Won, additional, Kuboki, Yasutoshi, additional, Meriggi, Fausto Angelo, additional, Cunningham, David, additional, Yeh, Kun-Huei, additional, Chan, Emily, additional, Chao, Joseph, additional, Tran, Qui, additional, Cremolini, Chiara, additional, and Pietrantonio, Filippo, additional

Published
2024
Full Text
View/download PDF

50. Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study

Author

Diaz, Luis A, Jr, Shiu, Kai-Keen, Kim, Tae-Won, Jensen, Benny Vittrup, Jensen, Lars Henrik, Punt, Cornelis, Smith, Denis, Garcia-Carbonero, Rocio, Benavides, Manuel, Gibbs, Peter, de la Fourchardiere, Christelle, Rivera, Fernando, Elez, Elena, Le, Dung T, Yoshino, Takayuki, Zhong, Wen Yan, Fogelman, David, Marinello, Patricia, and Andre, Thierry

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results